Endothelial dysfunction and atherosclerosis: Focus on novel therapeutic approaches

Recent Patents on Cardiovascular Drug Discovery

Volumn 7, Issue 1, 2012, Pages 21-32

  Briasoulis, Alexandros ^a   Tousoulis, Dimitris ^a   Androulakis, Emmanuel S ^a   Papageorgiou, Nikolaos ^a   Latsios, George ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Atherosclerosis; Endothelial dysfunction; Nitric oxide synthase; Patents

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ALDOSE REDUCTASE INHIBITOR; APOCYNIN; ARGINASE ANTAGONIST; ARGININE; ATENOLOL; ATORVASTATIN; CAPTOPRIL; CARDIOVASCULAR AGENT; CHOLESTEROL; CITRULLINE; CYCLOPENTENONE PROSTAGLANDIN; DIPHENYLIODONIUM SALT; ENALAPRILAT; EPOXYICOSATRIENOIC ACID; EZETIMIBE; FOLIC ACID; LIPOCORTIN 5; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEBIVOLOL; OXIDIZED LOW DENSITY LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RECOMBINANT HIGH DENSITY LIPOPROTEIN; SIMVASTATIN; TIE 1 RECEPTOR; UNCLASSIFIED DRUG; ZOFENOPRILAT;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TREATMENT INDICATION; VASCULAR ENDOTHELIUM;

ANIMALS; ATHEROSCLEROSIS; ENDOTHELIUM, VASCULAR; HUMANS; NITRIC OXIDE;

EID: 84857751950     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489012799362386     Document Type: Review

References (130)

1. Hare JM, Stamler JS. NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 2005; 115: 509-17.
2. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
3. Economou E, Tousoulis D, Katinioti A, Stefanadis C, Trikas A, Pitsavos C, et al. Chemokines in patients withischaemic heart disease and the effect of coronary angioplasty. Int J Cardiol 2001; 80: 55-60.
4. Tousoulis D, Davies GJ, Asimakopoulos G, Homaei H, Zouridakis E, Ahmed N, et al. Vascular cell adhesionmolecule-1 and intercellular adhesion molecule-1 serum level in patients with chest pain and normal coronary arteries (syndrome X). Clin Cardiol 2001; 24: 301-4.
5. Antoniades C, Tousoulis D, Tountas C, Tentolouris C, Toutouza M, Vasiliadou C, et al. Vascular endothelium andinflammatory process, in patients with combined type 2 diabetes mellitus and coronary atherosclerosis: the effects of vitamin C. Diabet Med 2004; 21: 552-8.
6. Tentolouris C, Tousoulis D, Antoniades C, Bosinakou E, Kotsopoulou M, Trikas A, et al. Endothelial function andproinflammatory cytokines in patients with ischemic heart disease and dilatedcardiomyopathy. Int J Cardiol 2004; 94: 301-5.
7. Nozaki T, Sugiyama S, Koga H, Sugamura K, Ohba K, Matsuzawa Y, et al. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol 2009; 54: 601-8.
8. Yeboah J, Folsom AR, Burke GL, Johnson C, Polak JF, Post W, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: The multiethnic study of atherosclerosis. Circulation 2009; 120: 502-9.
9. Dobarro D, Gómez-Rubín MC, Sanchez-Recalde A, Moreno R, Galeote G, Jimenez-Valero S, et al. Current pharmacological approach to restore endothelial dysfunction. Cardiovasc Hematol Agents Med Chem 2007; 7: 212-22.
10. Sudano I, Spieker LE, Hermann F, Flammer A, Corti R, Noll G, et al. Protection of endothelial function: targets for nutritional and pharmacological interventions. J Cardiovasc Pharmacol 2006; 47(Suppl 2): S136-50.
11. Halcox JP, Deanfield JE. Endothelial cell function testing: How does the method help us in evaluating vascular status? Acta Paediatr Suppl 2004; 93: 48-54.
12. Tousoulis D, Davies G, Crake T, Lerman A, Hasdai D, Holmes D. Acetylcholine and endothelial function. Circulation 1998; 98: 1587A-90.
13. Tousoulis D, Davies G, Lefroy DC, Haider AW, Crake T. Variable coronary vasomotor responses to acetylcholine in patients with normal coronary arteriograms: Evidence for localised endothelial dysfunction. Heart 1996; 75: 261-6.
14. Tousoulis D, Antoniades C, Stefanadis C. Evaluating endothelial function in humans: A guide to invasive and non-invasive techniques. Heart 2005; 91: 553-8.
15. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol 2003; 42: 1149-60.
16. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338: 1546-50.
17. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-41.
18. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: A statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 7-17.
19. Tousoulis D, Briasoulis A, Papageorgiou N, Tsioufis C, Tsiamis E, Toutouzas K, et al. Oxidative stress and endothelial function: therapeutic interventions. Recent Pat Cardiovasc Drug Discov 2011; 6: 103-14.
20. Antoniades C, Tousoulis D, Marinou K, Papageorgiou N, Bosinakou E, Tsioufis C, et al. Effects of insulin dependence on inflammatory process, thrombotic mechanisms and endothelial function, in patients with type 2 diabetes mellitus and coronary atherosclerosis. Clin Cardiol 2007; 30: 295-300.
21. Antoniades C, Tousoulis D, Marinou K, Stefanadi E, Ntarladimas I, Latsios G, et al. Effects of lipid profile on forearm hyperemic response in young subjects. Hellenic J Cardiol 2006; 47: 152-7.
22. Charakida M, Masi S, Lüscher TF, Kastelein JJ, Deanfield JE. Assessment of atherosclerosis: the role of flow-mediated dilatation. Eur Heart J 2010; 31: 2854-61.
23. Papamichael CM, Aznaouridis KA, Karatzis EN, Karatzi KN, Stamatelopoulos KS, Vamvakou G, et al. Effect of coffee on endothelial functionin healthy subjects: The role of caffeine. Clin Sci (Lond) 2005; 109: 55-60.
24. Leeson P, Thorne S, Donald A, Mullen M, Clarkson P, Deanfield J, et al. Non-invasive measurement of endothelial function: Effect on brachial artery dilatation of graded endothelial dependent and independent stimuli. Heart 1997; 78: 22-7.
25. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. International Brachial Artery Reactivity Task Force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65.
26. Ghiadoni L, Versari D, Giannarelli C, Faita F, Taddei S. Noninvasive diagnostic tools for investigating endothelial dysfunction. Curr Pharm Des 2008; 14: 3715-22.
27. Celermajer DS. Brachial artery FMD with 5-minute distal cuff occlusion - a useful pathophysiological test after all! J Appl Physiol 2005; 99: 1619.
28. Celermajer DS. Testing endothelial function using ultrasound. J Cardiovasc Pharmacol 1998; 32(Suppl 3): S29-32.
29. Bots ML, Westerink J, Rabelink TJ, de Koning EJ. Assessment of flow-mediated vasodilatation (FMD) of the brachial artery: Effects of technical aspects of the FMD measurement on the FMD response. Eur. Heart J 2005; 26: 363-8.
30. Leeson CP, Robinson M, Francis JM, Robson MD, Channon KM, Neubauer S, et al. Cardiovascular magnetic resonance imaging for non-invasive assessment of vascular function: Validation against ultrasound. J Cardiovasc Magn Reson 2006; 8: 381-7.
31. Kruger A, Stewart J, Sahityani R, O'Riordan E, Thompson C, Adler S, et al. Laser Doppler flowmetry detection of endothelial dysfunction in end-stage renal disease patients: correlation with cardiovascular risk. Kidney Int 2006; 70:157-64.
32. Liew G, Mitchell P, Rochtchina E, Wong TY, Hsu W, Lee ML, et al. Fractal analysis of retinal microvasculature and coronary heart disease mortality. Eur Heart J 2011; 32: 422-9.
33. Hamburg NM, Benjamin EJ. Assessment of endothelial function using digital pulse amplitude tonometry. Trends Cardiovasc Med 2009; 19: 6-11.
34. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation 2005; 111: 3481-8.
35. Muller G, Morawietz H. Nitric oxide, NAD(P)H oxidase, and atherosclerosis. Antioxid Redox Signal 2009; 11: 1711-31.
36. The multiple risk factor intervention trial (MRFIT). A national study of primary prevention of coronary heart disease. JAMA 1976; 235: 825-827.
37. de Jongh S, Lilien MR, Bakker HD, Hutten BA, Kastelein JJ, Stroes ES. Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis 2002; 163: 193-97.
38. Androulakis ES, Tousoulis D, Papageorgiou N, Tsioufis C, Kallikazaros I, Stefanadis C. Essential hypertension: Is there a role for inflammatory mechanisms? Cardiol Rev 2009; 17: 216-21.
39. Ambrose JA, Barua RS. The pathophysiology of cigarette smoking and cardiovascular disease: An update. J Am Coll Cardiol 2004; 43: 1731-7.
40. Aird WC. Endothelial biomedicine. New York, Cambridge University Press, 2007.
41. Armani C, Landini L Jr, Leone A. Molecular and biochemical changes of the cardiovascular system due to smoking exposure. Curr Pharm Des 2009; 15: 1038-53.
42. Naya M, Morita K, Yoshinaga K, Manabe O, Goto D, Hirata K, et al. Long-term smoking causes more advanced coronary endothelial dysfunction in middle-aged smokers compared to young smokers. Eur J Nucl Med Mol Imaging 2011; 38: 491-8.
43. Ozaki K, Hori T, Ishibashi T, Nishio M, Aizawa Y. Effects of chronic cigarette smoking on endothelial function in young men. J Cardiol 2010; 56: 307-13.
44. Clarkson P, Celermajer DS, Donald AE, Sampson M, Sorensen KE, Adams M, et al. Impaired vascular reactivity in insulin dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 1996; 28: 573-9.
45. Dogra G, Rich L, Stanton K, Watts GF. Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria. Diabetologia 2001; 44: 593-601.
46. Virdis A, Ghiadoni L, Cardinal H, Favilla S, Duranti P, Birindelli R, et al. Mechanisms responsible for endothelial dysfunction induced by fasting hyperhomocystinemia in normotensive subjects and patients with essential hypertension. J Am Coll Cardiol 2001; 38: 1106-15.
47. Glasser S, Selwyn A, Ganz P. Atherosclerosis: Risk factors and the vascular endothelium. Am Heart J 1996; 131: 379-84.
48. Esper RJ, Nordaby RA, Vilariño JO, Paragano A, Cacharrón JL, Machado RA. Endothelial dysfunction: A comprehensive appraisal. Cardiovasc Diabetol 2006; 5: 4.
49. Vita JA. Nitric oxide-dependent vasodilation in human subjects. Methods Enzymol 2002; 359: 186-200.
50. Antoniades C, Antonopoulos AS, Bendall JK, Channon KM. Targeting redox signaling in the vascular wall: From basic science to clinical practice. Curr Pharm Des 2009; 15: 329-42.
51. Tousoulis D, Charakida M, Stefanadis C. Endothelial function and inflammation in coronary artery disease. Heart 2006; 92: 441-4.
52. John S, Schmieder RE. Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. Curr Hypertens Rep 2003; 5: 199-207.
53. Tousoulis D, Antoniades C, Koumallos N, Marinou K, Stefanadi E, Latsios G, et al. Novel therapies targeting vascular endothelium. Endothelium 2006; 13: 411-21.
54. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, et al. Endothelial regulation of vasomotion in apoE-deficient mice: Implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001; 103: 1282-8.
55. Behrendt D, Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Cardiol 2002; 90: 40L-48L.
56. Le Brocq M, Leslie SJ, Milliken P, Megson IL. Endothelial dysfunction: From molecular mechanisms to measurement, clinical implications, and therapeutic opportunities. Antioxid Redox Signal 2008; 9: 1631-74.
57. Münzel T, Sinning C, Post F, Warnholtz A, Schulz E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2009; 40: 180-96.
58. Martin BJ, Anderson TJ. Risk prediction in cardiovascular disease: The prognostic significance of endothelial dysfunction. Can Jardiol 2009; 25: 15A-20A.
59. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 653-8.
60. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testingand clinical relevance. Circulation 2007; 115: 1285-95.
61. Rohani M, Jogestrand T, Kallner G, Jussila R, Agewall S. Morphological changesrather than flow-mediated dilatation in the brachial artery are better indicatorsof the extent and severity of coronary artery disease. J Hypertens 2005; 23:1397-402.
62. Halcox JP, Donald AE, Ellins E, Witte DR, Shipley MJ, Brunner EJ, et al. Endothelial function predicts progression of carotid intima-mediathickness. Circulation 2009; 119: 1005-12
63. Brevetti G, Silvestro A, Schiano V, Chiariello M. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: Additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation 2003; 108: 2093-8.
64. Chan SY, Mancini GB, Kuramoto L, Schulzer M, Frohlich J, Ignaszewski A. The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease. J Am Coll Cardiol 2003; 42: 1037-43.
65. Guazzi M, Reina G, Gripari P, Tumminello G, Vicenzi M, Arena R. Prognostic value of flow-mediated dilatation following myocardial infarction. Int J Cardiol 2009; 132: 45-50.
66. Takase B, Matsushima Y, Uehata A, Ishihara M, Kurita A. Endothelial dysfunction, carotid artery plaque burden, and conventional exercise-induced myocardial ischemia as predictors of coronary artery disease prognosis. Cardiovasc Ultrasound 2008; 6: 61.
67. Yeboah J, Crouse JR, Hsu FC, Burke GL, Herrington DM. Brachial flow-mediated dilation predicts incident cardiovascular events in older adults: The Cardiovascular Health Study. Circulation 2007; 115: 2390-7.
68. Tousoulis D, Papageorgiou N, Androulakis E, Paroutoglou K, Stefanadis C. Novel therapeutic strategies targeting vascular endothelium in essential hypertension. Expert Opin Investig Drugs 2010; 19: 1395-412.
69. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation, 1997; 95: 1126-31.
70. Antoniades C, Bakogiannis C, Leeson P, Guzik TJ, Zhang MH, Tousoulis D, et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 2011; 19; 124: 335-45.
71. Antoniades C, Bakogiannis C, Tousoulis D, Reilly S, Zhang MH, Paschalis A, et al. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation 2010; 122 (11 Suppl): S66-73.
72. Inoue I, Awata T, Katayama S. Retrospective, observation study: Quantitative and qualitative effect of ezetimibe and HMG-CoA eductase inhibitors on LDL-cholesterol: are there disappearance thresholds for small, dense LDL and IDL? Recent Pat Cardiovasc Drug Discov 2010; 5: 143-52.
73. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 2000; 6: 1004-10.
74. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biologic Chem 1998; 273: 24266-71.
75. Wagner AK, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61-9.
76. Wassmann S, Nickenig G. Interrelationship of free oxygen radicals and endothelial dysfunction-modulation by statins. Endothelium 2003; 10: 23-33.
77. Girona J, La Ville AE, Sota R, Plana N, Masana L. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 1999; 83: 846-51.
78. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23: 589-96.
79. Cominacini L, Pasini AF, Garbin U, Nava C, Davoli A, Criscuoli M, et al. Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation. J Am Coll Cardiol 2003; 42: 1838-84.
80. Pasini AF, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypert 2005; 23: 589-96.
81. Mason RP, Kalinowski L, Jacob RF, Jacoby AM, Malinski T. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 2005; 112: 3795-801.
82. Evangelista S, Garbin U, Pasini AF, Stranieri C, Boccioletti V, Cominacini L. Effect of dl-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells. Pharmacol Res 2007; 55: 303-9.
83. Oelze M, Daiber A, Brandes RP, Hortmann M, Wenzel P, Hink U, et al. Nebivolol prevents NADPH oxidase mediated superoxide formation and endothelial dysfunction in angiotensin II-treated rats. Hypertension 2006; 48: 677-84.
84. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part I: Oxidative stress and atherogenesis. Circulation 2002; 105: 393-96.
85. Pasini AF, Garbin U, Nava MC, Stranieri C, Pellegrini M, Boccioletti V, et al. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypert 2007; 20: 443-50.
86. Cominacini L, Pasini AF, Garbin U, Evangelista S, Crea AE, Tagliacozzi D, et al. Zofenopril inhibits the expression of adhesion molecules on endothelial cells by reducing reactive oxygen species. Am J Hypertens 2002; 15: 891-5.
87. Liu X, Engelman RM, Rousou JA, Cordis GA, Das DK. Attenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitors. Cardiovasc Drugs Ther 1992; 6: 437-43.
88. Mak IT, Freedman AM, Dickens BF, Weglicki WB. Protective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cells. Biochem Pharmacol 1990; 40: 2169-75.
89. Desideri G, Grassi D, Croce G, Bocale R, Tiberti S, Evangelista S, et al. Different effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: Evidence of an oxidant-sensitive pathway. Mediators Inflamm 2008; 2008: 305087.
90. Prasad A, Tupas-Habib T, Schenke WH, Mincemoyer R, Panza JA, Waclawin MA, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349-54.
91. Hsueh WA, Bruemmer D. Peroxisome proliferator-activated receptor gamma: Implications for cardiovascular disease. Hypertension 2004; 43:297-305.
92. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM. Peroxisome proliferator-activated receptor g ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 52-7.
93. Hwang J, Kleinhenz DJ, Lassegue B, Griendling KK, Dikalov S, Hart CM. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol 2005; 288: C899-C905.
94. Yew T, Toh SA, Millar JS. Selective Peroxisome proliferatoractivated receptor-modulation to reduce cardiovascular risk in patients with insulin resistance. Recent Pat Cardiovasc Drug Discov 2011 Oct 21.
95. Jialal I, Devaraj S. Antioxidants and atherosclerosis: Don't throw out the baby with the bath water. Circulation 2003; 107: 926-8.
96. Channon KM, Guzik TJ. Mechanisms of superoxide production in human blood vessels: Relationship to endothelial dysfunction, clinical and genetic risk factors. J Phys Pharmacol 2003; 53: 515-24.
97. Tousoulis D, Xenakis C, Tentolouris C, Davies G, Antoniades A, Crake T, Stefanadis C. Effects of vitamin C on intracoronary Larginine dependent coronary vasodilatation in patients with stable angina. Heart 2005; 91: 1319-23.
98. Lerman A, Burnett JC, Higano ST, McKinley LJ, Holmes DR. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998; 97: 2123-8.
99. Boger RH. Asymmetric dimethylarginine (ADMA): A novel risk marker in cardiovascular medicine and beyond. Ann Med 2006; 38: 126-36.
100. Antoniades C, Antonopoulos A, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: From folate fortification to the recent clinical trials. Eur Heart J 2009; 30: 6-15.
101. Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, et al. 5-Methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: Effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006; 114: 1193-201.
102. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-75.
103. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006; 354: 1578-88.
104. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006; 354: 1567-77.
105. Yu Z, Xu F, Huse LM, Morisseau C, Draper AJ, Newman JW, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 2000; 87: 992-8.
106. Schmelzer KR, Kubala L, Newman JW, Kim IH, Eiserich JP, Hammock BD. Soluble epoxide hydrolase is a therapeutic target for acute inflammation. Proc Natl Acad Sci USA 2005; 102: 9772-7.
107. Rubanyi, G., Webb, H.K., Gless, R.D., Jr., Anandan, S.K., Aavula, B.R., Patel, D.V., Wang, Y.X. Soluble Epoxide hydrolase inhibitor for the treatment of endothelial dysfunction. WO086426 (2009).
108. Carney, D., Olszewska-Pazdrak, B., Fossum, T., Method for the treatment of endothelial dysfunction. WO036387 (2008).
109. Meininger, C. Endothelium-targeting nanoparticle for reversing endothelialdysfunction. US20070086983 (2007).
110. Greco, E. L-citrulline for treating endothelial dysfunction and in particular erectile dysfunction. US20110044965 (2011).
111. Stroes, E. Treatment of endothelial dysfunction in diabetic patients. US20110190193 (2011).
112. Gutierrez LL, Maslinkiewicz A, Curi R, de Bittencourt PI Jr. Atherosclerosis: A redox-sensitive lipid imbalance suppressible by cyclopentenone prostaglandins. Biochem Pharmacol 2008; 75: 2245-62.
113. Homem de Bittencourt Jr PI, Lagranha DJ, Maslinkiewicz A, Senna SM, Tavares AM, Baldissera LP, et al. LipoCardium: Endothelium-directed cyclopentenone prostaglandinbased liposome formulation that completely reverse atherosclerotic lesions. Atherosclerosis 2007; 193: 245-58.
114. Santoro, M.G., Rossi, A., Elia, G., Garaci, E., Amici, C. Methods of treating inflammatory and viral disorders by administering yclopentenone compounds. US20050020687 (2005).
115. Spycher SE, Tabataba-Vakili S, O'Donnell VB, Palomba L, Azzi A. Aldose reductase induction: A novel response to oxidative stress of smooth muscle cells. FASEB J 1997; 11: 181-8.
116. Lo AC, Cheung AK, Hung VK, Yeung CM, He QY, Chiu JF, et al. Deletion of aldose reductase leads to protection against cerebral ischemic injury. J Cereb Blood Flow Metab 2007; 27: 1496-1509.
117. Gleissner CA, Sanders JM, Nadler J, Ley K. Upregulation of aldose reductase during foam cell formation as possible link among diabetes, hyperlipidemia, and atherosclerosis. Arterioscler Thromb Vasc Biol 2008; 28: 1137-43.
118. Le Naour, M., Pirat, C., Lebegue, N., Leclerc, V., Berthelot, P., Dacquet, C., Ktorza, A., Caignard, D.H. New heterocyclic compounds are aldose reductase inhibitors useful to treat e.g. hyperglycemia, dyslipidemia, non-insulin-dependant type II diabetes, syndrome X, coronary artery diseases, glomerulonephritis and psoriasis. FR2921366 (2009).
119. Holland, J., Johnson, D. Use of NADPH oxidase inhibitors for a manufacture of medicament for prevention of atherosclerosis. GR3033067 (2000).
120. Frostegard, J., Pettersson, K. Compounds and methods for the treatment of vascular disease. WO077764 (2009)
121. Sukhatme, V., Chan, C.B. Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders. US199426 (2008).
122. Antoniades, C., Shirodaria, C., Channon, K.M., Moser, R. Use of folates for the prevention and treatment of vascular diseases. US20080064702 (2008).
123. Schmidt TS, Alp NJ. Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin Sci (Lond) 2007; 113: 47-63.
124. Antoniades C, Shirodaria C, Crabtree M, Rinze R, Alp N, Cunnington C, et al. Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation. Circulation 2007; 116: 2851-2859.
125. Higashi Y, Sasaki S, Nakagawa K, Fukuda Y, Matsuura H, Oshima T, et al. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens 2002; 15: 326-32.
126. Porkert M, Sher S, Reddy U, Cheema F, Niessner C, Kolm P, et al. Tetrahydrobiopterin: a novel antihypertensive therapy. J Hum Hypertens 2008; 22: 401-7.
127. Schmidt TS, McNeill E, Douglas G, Crabtree MJ, Hale AB, Khoo J, et al. Tetrahydrobiopterin supplementation reduces atherosclerosis and vascular inflammation in apolipoprotein E-knockout mice. Clin Sci (Lond) 2010; 119: 131-42.
128. Antonopoulos AS, Lee R, Margaritis M, Antoniades C. Adiponectin as a regulator of vascular redox state: therapeutic implications. Recent Pat Cardiovasc Drug Discov 2011; 6: 78-88.
129. Yew T, Toh SA, Millar JS. Selective peroxisome proliferatoractivated receptor-modulation to reduce cardiovascular risk in patients with insulin resistance. Recent Pat Cardiovasc Drug Discov 2011 Oct 21.
130. Aliev G, Li Y, Palacios HH, Obrenovich ME. Oxidative stress induced mitochondrial DNA deletion as a hallmark for the drug development in the context of the cerebrovascular diseases. Recent Pat Cardiovasc Drug Discov 2011; 6: 222-41.